Correction: Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer

• by Luca D’Erme, Giacomo Avesani, Luca Russo, Silvia Bottazzi, Brandon Whitcher, Antonio Candito, Robby Emsley, Davide Meo, Alec Paschalis, Adam Sharp, Nina Tunariu, Dow-Mu Koh

• September 30, 2026

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

• October 15, 2026

• 1 min

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

• October 15, 2026

• 1 min

Nipple or skin-sparing mastectomy flap: can preoperative breast-MRI predict post-operative complications?

• by L. I. Sgaramella, A. Pasculli, F. P. Prete, F. Cofone, M. Moschetta, M. Maruccia, R. Elia, M. Telegrafo, V. De Ruvo, M. Bisceglie, M. M. Miccoli, F. Palma, C. Testini, G. Giudice, M. Testini, A. Gurrado

• October 13, 2026